Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStarting Mounjaro follows a structured, prescriber-led sequence: you begin at 2.5 mg, hold each dose for around four weeks while your body adjusts, then titrate upward only when your prescriber is satisfied it is appropriate. Every step is a clinical decision, not a calendar event. Mounjaro (tirzepatide) is a prescription-only medicine licensed in the UK for weight management, which means a GPhC-registered prescriber must assess your suitability before treatment begins and before each dose change. Understanding tirzepatide's dual mechanism helps make sense of why the stepped schedule exists: activating both GIP and GLP-1 receptors produces real physiological change, and the dose ladder is designed to let your system settle at each level before going further.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Before a single pen is dispensed, a prescriber reviews your full clinical picture. At our pharmacy, that review happens the same day you complete your consultation — a real clinician reads your answers, not software. Identity and weight are verified, your medical history is assessed, and the prescriber decides whether Mounjaro is appropriate for you.
If it is, treatment begins at 2.5 mg. Think of this first pen as your system's introduction to the medicine. The dose is deliberately low: nausea and other gastrointestinal effects are most common when tirzepatide is new to the body, and starting gently reduces the chance of them derailing things early. You inject once weekly, typically into the abdomen, thigh or upper arm, rotating sites each time. Storage is in the fridge (2–8°C) until you're ready to use each dose — the Mounjaro use-by and storage rules matter here, so always check the Patient Information Leaflet for the exact out-of-fridge window rather than going by memory.
Most people find the first four weeks manageable. Appetite often begins to shift noticeably even at 2.5 mg, though the primary purpose of this phase is adjustment, not weight change. Stick to the schedule your prescriber has set, and flag anything unexpected via aftercare before deciding anything yourself.
After four weeks at 2.5 mg, the schedule typically moves to 5 mg, then 7.5 mg, and so on, each strength held for roughly four weeks before the next increase is considered. The word "considered" matters: titration is not automatic. At each repeat, a prescriber reviews your weight progress, any side effects you've reported, and whether moving up is clinically appropriate. Rushing the ladder doesn't improve results; it usually just increases side effects.
The gastrointestinal effects that are most common with tirzepatide (nausea, loose stools, reduced appetite, occasional reflux) tend to peak shortly after a dose increase and ease within a week or two for most people. The day-by-day experience in the first weeks varies between individuals, but the pattern of "adjustment period then settling" is consistent across the clinical programme. NHS patient guidance on tirzepatide at nhs.uk/medicines/tirzepatide details what to expect at each stage and when symptoms warrant medical attention.
Practically: if you order before midday on a weekday, your next pen arrives the following working day via DPD. That rhythm fits neatly around a regular injection day, many people choose the same day each week, something that doesn't move around (a Sunday evening, say, or a Monday before the school run).
The maintenance dose is the highest strength you can tolerate and that your prescriber judges appropriate, anywhere from 5 mg to 15 mg depending on your response and tolerability. Not everyone reaches 15 mg, and that is fine; the trials show meaningful weight reduction at every dose level above the starter. In SURMOUNT-1, involving thousands of adults, average body-weight reduction at 15 mg reached around 20–21% over 72 weeks, as published in the New England Journal of Medicine. Lower maintenance doses produced lower but still clinically significant results.
Once you are stable at your maintenance dose, the clinical re-review continues with every repeat. There are no automatic renewals at our service; each order is individually assessed. NICE's appraisal of tirzepatide (TA1026) sets the benchmark for when to review whether treatment is still working: if weight loss is below 5% after six months at the highest tolerated dose, continuing is not recommended. Your prescriber will have that conversation with you before it becomes an issue.
For context on what this stage costs over time, the Eli Lilly UK price changes page sets out how private treatment pricing has moved and what to expect at different dose levels, useful reading before you reach the higher strengths.
The clinical schedule is the backbone, but a few practical habits make it easier. Inject on the same day each week. Rotate sites consistently to avoid localised discomfort. Keep the pen refrigerated and let it reach room temperature for a few minutes before injecting. If a dose is missed, follow the Patient Information Leaflet guidance, the timing rules depend on how close the missed dose is to the next one, and this is exactly the kind of question our aftercare team handles seven days a week, rather than something to guess at.
Mounjaro works alongside a reduced-calorie diet and increased physical activity, not instead of them. The medicine reduces appetite significantly for most people; using that window to build sustainable habits is the point. Protein intake, hydration and strength activity all matter more than they might seem when appetite is suppressed. Your prescriber or a registered dietitian can advise on specifics.
Any concerns about how the medicine is affecting you (physical or psychological) are worth raising with a clinician rather than leaving. The common concerns people raise about Mounjaro page covers the questions our prescribers hear most often. If you are still weighing up whether this treatment is right for you, check your eligibility with a free consultation and let a prescriber give you a straight answer based on your own picture.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.